Receptor tyrosine kinases of the Eph family become tyrosine phosphorylated and initiate signalling events upon binding of their ligands, the ephrins. Eph receptors such as EphA2 and EphB4 are highly expressed but poorly tyrosine phosphorylated in many types of cancer cells, suggesting a limited interaction with ephrin ligands. Nevertheless, decreasing the expression of these receptors affects the malignant properties of cancer cells, suggesting that Eph receptors may influence cancer cells independently of ephrin stimulation. Ligand-independent activities of Eph receptors in cancer, however, have not been demonstrated. By using siRNA (small interfering RNA) to downregulate EphB4 in MCF7 and MDA-MB-435 cancer cells, we found that EphB4 inhibits integrin-mediated cell substrate adhesion, spreading and migration, and reduces β1-integrin protein levels. Low expression of the EphB4 preferred ligand, ephrin-B2, and minimal contact between cells in these assays suggest that cell contact-dependent stimulation of EphB4 by the transmembrane ephrin-B2 ligand does not play a role in these effects. Indeed, inhibitors of ephrin-B2 binding to endogenous EphB4 did not influence cell substrate adhesion. Increasing EphB4 expression by transient transfection inhibited cell substrate adhesion, and this effect was also independent of ephrin stimulation because it was not affected by single amino acid mutations in EphB4 that impair ephrin binding. The overexpressed EphB4 was tyrosine phosphorylated, and we found that EphB4 kinase activity is important for inhibition of integrin-mediated adhesion, although several EphB4 tyrosine phosphorylation sites are dispensable. These findings demonstrate that EphB4 can affect cancer cell behaviour in an ephrinindependent manner.
INTRODUCTION
High expression of the EphB4 receptor has been documented in a large variety of human cancers, including breast, ovarian and prostate cancer, early colorectal cancer and others [1] [2] [3] [4] [5] [6] [7] [8] [9] . In the corresponding cancer cell lines, EphB4 is also widely expressed, but its level of tyrosine phosphorylation is often low [3] [4] [5] [6] 9, 10] , suggesting low levels of activation by its preferred ligand, ephrin-B2. Consistent with this, ephrin-B2 is poorly expressed in many of the cancer cell lines. Whether other mechanisms may also contribute to low EphB4 activation by ephrin-B2 in cancer cells remains to be investigated. For example, loss of E-cadherin in cancer cells has been shown to impair EphA2 activation by the GPI (glycosylphosphatidylinositol)-linked ephrin-A1 ligand, suggesting a requirement for stable cell-cell contacts [11] .
Interestingly, we found that inducing activation of EphB4 with a soluble form of ephrin-B2 (ephrin-B2 Fc) inhibits the tumorigenicity of MCF7, MDA-MB-231 and MDA-MB-435 cancer cells through a pathway that involves Abl family cytoplasmic tyrosine kinases and the adaptor protein Crk [10] . This tumour suppressor pathway appears to be operational in different types of cancer cells because MCF7 and MDA-MB-231 are breast cancer cells, whereas the currently used MDA-MB-435 cell line has been recently shown to be derived from the M14 melanoma cell line [12] . Downregulation of EphB4 using RNA interference or antisense oligonucleotides has also provided evidence for a functional role of EphB4 in a variety of cancer cell types where this receptor appears to be phosphorylated (activated) at low levels [3, 4, 7, 9] .
EphB4 is part of the large Eph family of receptor tyrosine kinases, which comprises EphA and EphB receptors. Prototypical Eph receptor activation takes place upon cell contact-dependent interaction with the ephrin ligands, which comprise the GPIlinked A-ephrins and the transmembrane B-ephrins [13] . Binding to ephrins on adjacent cells triggers Eph receptor autophosphorylation and activation of the kinase domain, initiating Eph receptor signalling activities. However, the functional importance of Eph receptors in cancer cells where they do not appear to be extensively activated by their ephrin ligands has led to the hypothesis that these receptors might influence the properties of cancer cells through ephrin-independent mechanisms [13] [14] [15] . A few reports raise the intriguing possibility that the Eph receptors might indeed be able to influence cell behaviour independently of ephrin binding. For example, genetic experiments have suggested an ephrin-independent function for the Caenorhabditis elegans Eph receptor, VAB-1, in gonadal sheath cell contraction [16] . Furthermore, forced expression of the EphA8 receptor in a neural cell line has been shown to promote MAPK (mitogen-activated protein kinase) activation and neurite outgrowth even when the receptor lacks the amino terminal ephrin-binding domain [17] . Very recently, ligand-independent activities have been reported for the EphA4 receptor in neural cells, where cytoplasmic fragments generated by γ -secretase or caspase cleavage affect dendritic spine morphogenesis and cell survival respectively [18, 19] . However, ligand-independent activities of Eph receptors in cancer have not been demonstrated. Here we report that the EphB4 receptor can modulate integrin-mediated adhesion in cancer cells independently of ephrin binding.
EXPERIMENTAL

Cell lines and transfections
MDA-MB-435p (parental), MDA-MB-435c (clonal) and HEK-293 (human embryonal kidney 293) cells were grown in DMEM (Dulbecco's modified Eagle's medium) with 10 % FBS (fetal bovine serum). MDA-MB-435c is a clonal cell line derived from MDA-MB-435p which expresses predominantly EphB4 among the EphB receptors [10] . MCF7 cells were grown in MEM (modified Eagle's medium) with 10 μg/ml insulin and 10 % FBS.
To knock down human EphB4, we tested Dharmacon siGENOME individual siRNAs (small interfering RNAs; Dharmacon RNA Technologies) and the Dharmacon SMARTpool of the four siRNAs. Individual siRNAs 1-4 correspond respectively to Dharmacon siGENOME duplex-5 (sense sequence GGACAAACACGGACAGUAUUU and antisense sequence 5 -PAUACUGUCCGUGUUUGUCCUU, where P indicates phosphorylation), duplex-6 (sense sequence GUACUAAGGUCU-ACAUCGAUU and antisense sequence 5 -PUCGAUG-UAGACCUUAGUACUU), duplex-7 (GGAGAGAAGCAGAA-UAUUCUU and antisense sequence 5 -PGAAUAUUCUGC-UUCUCUCCUU), duplex-8 (sense sequence GCCAAUAG-CCACUCUAACAUU and antisense sequence 5 -PUGUUA-GAGUGGCUAUUGGCUU). siRNA that engages the RISC (RNA-induced silencing complex) complex but does not match any mouse or human genes (Dharmacon siCONTROL nontargeting siRNA) was used as a control. The amount of siRNA and transfection protocol were optimized for each cell line. The pcDNA3-EphB4 plasmid was a gift from D.T. Scadden (MGH Cancer Center, Harvard University, Boston, MA, U.S.A.) and pEGFP (where EGFP, enhanced green fluorescent protein) was from Clonetech. The EphB4 590/594E mutant has been described in [20] and the other EphB4 mutants were generated by site-directed mutagenesis with the QuikChange ® sitedirected mutagenesis kit (Stratagene) using pcDNA3-EphB4 as the template. For transfections of the plasmids in HEK-293 cells, cells in 6-cm-diameter plates were transfected with 5 μg DNA and 15 μl FuGENE TM (Roche Applied Science). Plasmids were transfected in MDA-MB-435p cells with Lipofectamine TM /PLUS according to the manufacturer's instructions. The cells were used 2 days after transfection.
Adhesion assays
For the experiments shown in Figure 1 , coverslips and culture dishes for adhesion assays were coated with 25 μg/ml fibronectin or 10 μg/ml poly-L-lysine (Sigma) for 1 h at 37
• C and then blocked with 1 % BSA in DMEM. For the experiments shown in Supplementary Figures S2(A) and S2(B), coverslips were coated with various concentrations of fibronectin (2-40 μg/ml) or collagen (15-90 μg/ml) and for those shown in Supplementary  Figure S2 (C), coverslips were coated with 5 μg/ml fibronectin. Cells transfected with siRNA or plasmids were used 3 and 2 days after transfection respectively.
In the experiments shown in Figure 4 , cells were washed with PBS, detached in 0.2 mM EDTA in PBS, washed twice with DMEM, kept in suspension for 30 min in 0.5 % (v/v) BSA in DMEM, and then plated in the same medium. For the experiments shown in Figure 4 , cells were kept in suspension for 10 min and then treated in suspension for 20 min with either 15 μg/ml EphB4 Fc, Fc control (R&D Systems) or 50 μM TNYL-RAW antagonistic peptide [21] . Untreated cells were used as a further control. For the experiments shown in Figure 4 (D), cells were then stimulated for 10 min with 5 μg/ml ephrin-B2 Fc or control human Fc, pre-clustered with 25 μg/ml anti-human Fc polyclonal antibody, in the continued presence of the inhibitors. To calculate relative cell attachment, the number of attached cells was normalized to that of control attached cells. In experiments including different substrate concentrations or time points, the control plated with the highest substrate concentration or for the longest time was used for normalization.
Immunofluorescence labelling
Cells plated on glass coverslips were fixed in 3.7 % formaldehyde in PBS, permeabilized in 0.5 % Triton X-100 in TBS (50 mM Tris/HCl, pH 7.0, and 150 mM NaCl) and incubated with 0.7 μg/ml anti-paxillin monoclonal antibody (BD Biosciences) or 0.5 μg/ml anti-phosphotyrosine monoclonal antibody (BD Biosciences), and subsequently incubated with Alexa conjugated anti-mouse secondary antibodies from Molecular Probes. Cells were also labelled with rhodamine phalloidin and DAPI (4 ,6-diamidino-2-phenylindole; Molecular Probes).
Immunoprecipitation and immunoblotting
For ephrin-B2 Fc stimulation experiments, adherent or suspended MDA-MB-435c cells were stimulated for 15 min with 3 μg/ml ephrin-B2 Fc (R&D Systems) pre-clustered by incubation with 0.3 μg/ml anti-human Fc polyclonal antibody (Jackson ImmunoResearch; Figure 6C ), for 20 min with 1.5 μg/ml ephrin-B2 Fc pre-clustered with 4.5 μg/ml anti-Fc antibody ( Figure 6D ) or for 20 min with 5 μg/ml ephrin-B2 Fc preclustered by incubation with 25 μg/ml anti-human Fc antibody ( Figure 3B ). In the experiments shown in Figures 6(C) and 6(D), cells were serum-starved overnight prior to stimulation. For immunoprecipitation, MDA-MB-435c cells and transiently transfected HEK-293 cells were lysed in modified RIPA buffer (50 mM Tris/HCl, pH 7.6, 150 mM NaCl, 1 % Triton X-100, 0.5 % sodium deoxycholate, 0.1 % SDS and 2 mM EDTA with protease and phosphatase inhibitors) and EphB4 was immunoprecipitated with anti-EphB4 polyclonal antibodies [10] . The immunoprecipitates were separated by SDS/PAGE and probed by immunoblotting with anti-phosphotyrosine antibodies (PY20, BD Biosciences), anti-EphB4 polyclonal antibodies [10] , anti-EphB4 monoclonal antibodies (Invitrogen/Zymed) or antibodies to the Tyr 590 and Tyr 594 juxtamembrane phosphorylation sites [22] . Lysates from siRNA-or plasmid-transfected cells were lysed in RIPA buffer and analysed by SDS/PAGE followed by immunoblotting with anti-EphB4 antibodies, anti-β1 integrin (BD Bioscience), anti-actin or anti-tubulin antibodies (Sigma). It should be noted that some transfected EphB4 mutants tended to be expressed at lower levels than wild-type EphB4. Therefore, the amounts of cell lysates used for immunoprecipitation or immunoblotting were adjusted to obtain comparable levels of EphB4.
Cell motility assays
We used the Cell Motility HitKit TM from Cellomics to measure random migration of cells. Black μClear flat bottom 96-well plates (Greiner Bio-One) were coated with the indicated concentrations of collagen or 25 μg/ml fibronectin, and subsequently coated with a blue fluorescent bead monolayer. Three days after transfection with siRNA, 500 cells/well were allowed to migrate in the presence of 5 % FBS for 18 h, and then were fixed and stained with rhodamine phalloidin to verify the location of the cells. Beads and cells were visualized using a fluorescence microscope, five 10× pictures were taken from 4 wells per condition, and 22-48 cells were counted per well. Only the blue channel, showing the beads' fluorescence, is shown in the images in Figure 2 (A). The area cleared by migrating cells, including the area occupied by the cells, was measured using Image J.
ELISA assays
To examine the ability of wild-type and mutant EphB4 to bind ephrin-B2, protein-A-coated 96 well plates (Pierce) were incubated with 1 μg/ml anti-EphB4 polyclonal antibodies or rabbit IgG control in 3 % BSA in TBST (TBS plus 0.01 % Tween) for 1 h at room temperature (∼ 22
• C). Wells were washed three times with wash buffer (TBST plus 1 mM CaCl 2 ) and then incubated with lysates from HEK-293 cells transfected with wild-type EphB4 or the indicated EphB4 mutants for 1.5 h. Wells were washed and incubated with ephrin-B2 fused to alkaline phosphatase for 1 h [21] . Ephrin-B2 alkaline phosphatase remaining bound after washing was detected by measuring alkaline phosphatase activity using the substrate p-nitrophenyl phosphate. Absorbance at 405 nm was measured using an ELISA plate reader.
RESULTS
EphB4 knockdown increases cancer cell adhesion, spreading and migration
Substantial evidence shows that Eph receptors regulate integrin activity when stimulated by ephrin ligands [23] [24] [25] . To investigate whether in cancer cells EphB4 might affect integrin-mediated cell substrate adhesion and migration independently of activation by ephrin-B2, we downregulated EphB4 expression using RNA interference. Four different EphB4 siRNAs that were transfected all effectively knocked down EphB4 expression in the MDA-MB435c clonal cell line, which expresses high levels of EphB4 [10] ( Figure 1A) . A pool of the four siRNAs yielded even greater EphB4 downregulation. The siRNA pool also effectively reduced EphB4 levels in the MCF7 breast cancer cell line, which also has high levels of EphB4 ( Figure 1A ). EphB4 expression was already decreased 24 and 48 h after siRNA transfection, and better downregulation was observed at 72 h (Supplementary Figure S1 at http://www.BiochemJ.org/bj/422/bj4220433add.htm). The parental MDA-MB-435p cell line, which has very low levels of EphB4 [10] , was used as a control to identify possible off-target effects ( Figure 1A ).
We measured cell attachment to fibronectin and collagen, two extracellular matrix ligands for β1 integrins [26] , which are a class of integrins known to be regulated by Eph receptors [23] [24] [25] and are well expressed in both MDA-MB-435 and MCF7 cells [27, 28] . We found that MDA-MB435c and MCF7 cells transfected with the EphB4 siRNA pool adhere faster than control siRNA-transfected cells to surfaces coated with a range of fibronectin and collagen concentrations ( Figure 1B and Supplementary Figures S2A and S2B at http://www.BiochemJ.org/bj/422/bj4220433add.htm). On the other hand, adhesion to poly-L-lysine, which is not mediated by integrins, was not affected by EphB4 expression ( Figure 1B ; Supplementary Figure S2A ). The increased adhesion observed at 30 min reflects a faster attachment rate of the cells in which EphB4 is downregulated, whereas maximal levels of attachment at longer time points were similar in EphB4 knockdown and control cells (Supplementary Figure S2C) . Immunofluorescence labelling of the cells for phosphotyrosine, the focal adhesion marker paxillin and the actin cytoskeleton revealed that the cells with decreased levels of EphB4 also spread faster on fibronectin compared with cells transfected with control siRNA ( Figure 1C) . Interestingly, the MDA-MB-435p cells, where EphB4 expression is already low, also spread faster than the MDA-MB-435c cells ( Figures 1B and  1C) . Furthermore, the EphB4 siRNAs did not significantly affect MDA-MB-435p attachment and spreading ( Figures 1B and 1C) .
In lateral migration assays on fibronectin, EphB4 siRNAmediated knockdown increased the migration of MDA-MB-435c and MCF7 cells, but did not have significant effects on the control MDA-MB-435p cells (Figures 2A and 2B ). Increased migration was also observed for EphB4 siRNA-transfected MCF7 cells plated on collagen ( Figure 2C ). Interestingly, EphB4 downregulation did not affect cell migration on collagen coated at 15 μg/ml compared with 90 μg/ml, whereas cell attachment was increased by the higher collagen concentration (Supplementary Figure S2B) , suggesting a different dependence of cell attachment and migration on substrate concentration. Although EphB4 knockdown has been reported to reduce MCF7 cell growth [4] , under our assay conditions we did not detect significant changes in the proliferation of MCF7 and MDA-MB-435c cells transfected for 48 or 72 h with EphB4 siRNAs compared with cells transfected with control siRNA (results not shown).
Probing lysates from EphB4 siRNA-transfected MCF7 cells with anti-β1 integrin antibodies revealed increased β1 integrin levels ( Figure 3A) , suggesting that the presence of endogenous EphB4 may inhibit cell attachment and movement by decreasing β1 integrin levels. In contrast, EphB4 activation by ephrin-B2 Fc did not affect β1-integrin expression ( Figure 3B ), consistent with previous findings with other activated Eph receptors [24, 25] .
Endogenous EphB4 inhibits cell attachment and spreading independently of ephrin binding
The increase in substrate adhesion, spreading and migration observed after EphB4 downregulation in cells with low ephrin-B2 expression and low EphB4 phosphorylation [10] suggests that these activities of EphB4 are either stimulated by low levels of ephrin-B2 or independent of ephrin binding. To distinguish between these two possibilites, we performed cell attachment assays in the presence of a soluble form of the EphB4 extracellular domain fused to Fc (EphB4 Fc) to inhibit the possible interaction between endogenous EphB4 and ephrin-B2. We also used the TNYL-RAW antagonistic peptide, which blocks the highaffinity ephrin-binding site of EphB4 [21, 29] . Both EphB4 Fc and the TNYL-RAW peptide have been shown to effectively inhibit activation of EphB4 by endogenous ephrin-B2 in cultured cells [10] . However, they did not affect cancer cell attachment ( Figures 4A-4C ) and spreading on fibronectin (results not shown). These results are consistent with the notion that EphB4 can inhibit cell adhesion independently of its ability to bind ephrin-B2.
EphB4 activation by ephrin-B2 Fc inhibited MCF7 cell attachment ( Figure 4D ), as reported for activation of other Eph receptors [22] [23] [24] [25] 30] , and both EphB4 Fc and the TNYL-RAW peptide effectively neutralized the effect of ephrin-B2 ( Figure 4D ). Because ephrin-B2 Fc stimulation did not affect β1-integrin levels ( Figure 3B ), inhibition of cell substrate attachment by ephrin-B2 probably involves inhibition of integrin activity rather than expression.
EphB4 mutants deficient in ephrin binding inhibit cell attachment and spreading
We performed additional experiments to investigate the role of ephrin binding in the effects of EphB4 on cell adhesion. We designed EphB4 mutants with impaired ligand-binding ability based on the results of prior mutagenesis experiments with the related EphA3 receptor as well as on available structural information for EphB2 in complex with ephrin-B2, and EphB4 in complex with the TNYL-RAW peptide [29, 31, 32] . We targeted Thr 93 and Thr 147 in the high-affinity ephrin-binding site of EphB4 because they were shown to play an important role in ligand binding in the prior studies. Lysates from HEK-293 cells transiently transfected with wild-type and mutant EphB4 were incubated in ELISA wells coated with antibodies to the EphB4 carboxy-terminal region to capture EphB4. By measuring binding of ephrin-B2 alkaline phosphatase to the immobilized EphB4 receptor in ELISA assays, we found that mutation of Thr 147 to either glycine (T147G) or leucine (T147L) does not substantially affect interaction with ephrin-B2 ( Figure 5A ), even though the T147G mutation inhibited binding of the TNYL-RAW peptide (results not shown). Mutation of the same threonine to arginine (T147R), however, drastically reduced ephrin-B2 binding to EphB4 ( Figure 5A ). Furthermore, mutation of Thr 93 to glutamine (T93Q) eliminated any detectable association of EphB4 with ephrin-B2. The T147R and T93Q mutants also did not bind the TNYL-RAW peptide (results not shown). Binding of ephrin-B1 alkaline phosphatase to EphB4 was not detectable in these assays (results not shown), consistent with the known low binding affinity of EphB4 for ephrin-B1 and other ephrin ligands except ephrin-B2 [33] . The transfected EphB4 mutants with defective ephrin-B2 binding ability exhibited similar levels of tyrosine phosphorylation to the wild-type EphB4 ( Figure 5B ), indicating that the observed phosphorylation of overexpressed EphB4 does not depend on ephrin stimulation and may be induced as a result of ligand-independent clustering occuring at high receptor levels [34] or of EphB4 crosstalk with receptors activated by serum growth factors [9] .
To examine the importance of ephrin-B2 binding in the effects of transfected EphB4 on cell attachment, we used MDA-MB-435p cells, which have low levels of endogenous EphB4. Transient transfection of wild-type EphB4 inhibited cell adhesion to fibronectin ( Figure 5C ), as well as cell spreading (results not shown). The transfected T93Q and T147R mutants, which have impaired ephrin-B2 binding ability, inhibited cell substrate adhesion as effectively as wild-type EphB4 ( Figure 5C ), indicating that ephrin-B2 binding is not required for the effects of transfected EphB4 on MDA-MB-435 cell attachment and spreading on fibronectin.
Kinase activity is required for ligand-independent inhibition of cell attachment and spreading by transfected EphB4
We next investigated whether EphB4 kinase activity and tyrosine phosphorylation play a role in the observed inhibition of cell adhesion to fibronectin. Transfection of an EphB4 mutant with an inactive kinase domain (K647R) did not inhibit cell attachment ( Figure 6A) . Furthermore, mutation of Tyr 606 to aspartic acid (Y606D) and of Tyr 590 and Tyr 594 to glutamic acid (Y590/594E) slightly increased the ability of EphB4 to inhibit cell attachment and spreading ( Figure 6A and results not shown), consistent with the fact that these mutations facilitate catalytic activity by destabilizing the inhibitory interaction of the juxtamembrane domain with the kinase domain [35] [36] [37] . Tyr 590 and Tyr 594 in the juxtamembrane region of EphB4 are conserved in all Eph receptors and represent major ephrindependent autophosphorylation sites as well as binding sites for SH2 (Src homology 2) domain-containing proteins [23] . However, we found that mutation of these tyrosines to glutamic acid, which does not support binding of SH2 domains [38] , did not reduce the ability of EphB4 Y590/594E to inhibit integrin-mediated MDA-MB-435c cell adhesion ( Figure 6A ). Mutation of another tyrosine phosphorylation site in the C-terminal SAM (sterile alpha motif) domain of EphB4 (Y924F) also did not reduce inhibition of cell adhesion by EphB4 ( Figure 6A ). Thus the binding of SH2 or PTB (phosphotyrosine-binding) domain-containing effector proteins to the Tyr 590 , Tyr 594 or Tyr 924 phosphorylated motifs in EphB4 is not critical for modulation of cell adhesion by EphB4.
Interestingly, inhibition of cell adhesion did not seem to correlate with the tyrosine phosphorylation levels of overexpressed EphB4, because the EphB4 Y924F mutant inhibited adhesion as well as wild-type EphB4 although it was much less phosphorylated ( Figure 6B) . Phosphorylation of the EphB4 Y590/594E mutant was also lower than wild-type, but this is probably due to the fact that the two mutated juxtamembrane tyrosines are major Eph receptor autophosphorylation sites [39] .
We did not detect tyrosine phosphorylation of endogenous EphB4 in cells attaching to a fibronectin substrate using either an anti-phosphotyrosine antibody or a phosphospecific antibody recognizing the phosphorylated Tyr 590 and Tyr 594 ( Figure 6C , FN lane). In contrast, ephrin stimulation caused prominent phosphorylation of these juxtamembrane tyrosines, as expected ( Figure 6C , ephrin-B2 lanes). Furthermore, we detected lower levels of EphB4 tyrosine phosphorylation when the MDA-MB435c cells were stimulated with ephrin-B2 Fc in suspension compared with adherent cells (Figure 6D ). Thus, integrinmediated attachment enhances ephrin-dependent EphB4 tyrosine phosphorylation, whereas EphB4 kinase activity inhibits integrindependent cell adhesion.
DISCUSSION
Ligand-independent functions of Eph receptors in cancer have been hypothesized in order to reconcile some of the results reported in the literature [9, [13] [14] [15] . However, there has been no conclusive evidence demonstrating ligand-independent activities of Eph receptors in cancer. We show here that the EphB4 receptor expressed in cancer cells can inhibit cell-substrate adhesion and cell spreading independently of stimulation by its ligand, ephrin-B2.
It is well documented that Eph receptor activation by ephrins can inhibit cell substrate adhesion by regulating the activity of β1 and other integrins through signalling effectors such as the Ras family GTPases, R-Ras and Rap1 [23] [24] [25] 40] . Eph receptors may also inhibit cell attachment by promoting dephosphorylation . from triplicate measurements. ***P < 0.001 for EphB4 constructs compared with vector control using one-way ANOVA and Tukey's post-hoc test. There was no significant difference in adhesion to fibronectin between wild-type EphB4 and the T147R and T93Q mutants.
of components of integrin signalling complexes, such as p130Cas and Fak, or by sequestering them away from nascent adhesion complexes [10, 24, 41, 42] . We now show that EphB4 can also inhibit cell substrate attachment independently of ephrin binding, concomitant with regulation of β1 integrin protein levels. Furthermore, we found that integrin-mediated adhesion potentiates ephrin-B2-induced EphB4 tyrosine phosphorylation. This suggests that integrins can in turn modulate the liganddependent activities of EphB4, as is the case for several other receptor tyrosine kinases [26, [43] [44] [45] .
We used several approaches to demonstrate that the EphB4 effects observed are ligand independent. First, in the attachment, spreading and migration assays, the cells were kept sparse to minimize contact between cells. Thus, EphB4 could not be substantially activated through ephrin binding at sites of cellcell contact. In any case, the levels of endogenous ephrin-B2 in the MCF7 and MDA-MB-435 cells used are low to undetectable [10] . Secondly, inhibitors of ephrin-B2-EphB4 interaction, such as EphB4 Fc and the TNYL-RAW competitive antagonistic peptide, did not influence integrin-mediated adhesion. These results suggest that ligand binding does not play a role in the effects we observed in cells expressing endogenous EphB4. Thirdly, the EphB4 T93Q and T147R mutants, which we have shown to be severely defective in ligand binding, were as effective as EphB4 wild-type in inhibiting cell attachment when expressed in cells with low EphB4 levels.
Given the high binding affinity of the Eph receptor-ephrin association and the large size of the ephrin binding pocket [46] , it is remarkable that changing a single amino acid is sufficient to disrupt ephrin binding. That these single amino acid mutations in the high-affinity ephrin-binding domain of an Eph receptor can impair ephrin binding was first proposed based on the phenotypes of C. elegans mutants [47, 48] , and was more recently conclusively demonstrated using biochemical approaches [32] . Thr  93 and Thr   147 are located in the high-affinity ephrin-binding pocket of EphB4 and contribute important interactions with ligands such as ephrin-B2 and the TNYL-RAW peptide [29, 31, 49] . Furthermore, these two residues appear to have a conserved role in the binding of different ephrins to Eph receptors because mutation of one of the corresponding amino acids of an EphA receptor (T102A and F152L of EphA3) was also shown to disrupt binding of an ephrin-A ligand [32] . Importantly, the T102A and F152L mutations have been shown to essentially abrogate ephrin binding without disrupting the overall conformation of the EphA3 receptor [32] . Thus, the corresponding T93Q and T147R mutations in EphB4 are unlikely to disrupt the overall three-dimensional structure of the ephrinbinding domain. It has also been reported that another single amino acid mutation (L95R) drastically reduces the binding affinity of EphB4 for ephrin-B2 and the TNYL-RAW peptide [49] . All of these mutants will be useful to further characterize ephrin-independent activities of the EphB4 receptor in cancer cells.
Higher β1 integrin levels in cancer cells where endogenous EphB4 is downregulated probably explain, at least in part, the observed increases in cell adhesion, spreading and migration. It will be interesting in the future to determine whether the ephrin-independent regulation of β1-integrin levels by EphB4 occurs at the transcriptional or post-transcriptional level, and to elucidate the mechanism involved in this novel form of Eph receptor/integrin crosstalk.
A possible model to explain our findings is that integrinmediated cell attachment promotes EphB4 kinase activity, causing a negative feedback loop that in turn limits integrin expression. Several other receptor tyrosine kinases are known to interact with integrins and/or become activated upon cell attachment in a ligand-independent manner [26, [43] [44] [45] . However, the adhesion-dependent activation of receptor tyrosine kinases typically correlates with their increased tyrosine phosphorylation, whereas we did not detect phosphorylation of endogenous EphB4 during cell attachment to fibronectin. Furthermore, we did not detect EphB4 immunolabelling in forming focal contacts and focal adhesions marked with paxillin or phosphotyrosine antibodies (results not shown), suggesting that a mechanism involving physical interaction of EphB4 with integrins in focal adhesions is also unlikely. On the other hand, integrin-mediated adhesion may affect only a subset of EphB4 molecules located in a strategic position to in turn regulate integrin levels [50] , whereas overall EphB4 phosphorylation remains too low for detection. Availability of a selective EphB4 kinase inhibitor would greatly help determine whether kinase activity is important in the regulation of cell attachment by endogenous EphB4, as observed for transfected EphB4.
A requirement for kinase activity in the inhibition of cell adhesion by a transiently transfected Eph receptor has been previously reported, but the importance of ephrin binding was not investigated [38, 40] . It is conceivable that Eph receptor clustering due to high levels of expression or crosstalk with activated growth factor receptors may lead to increased kinase activity even in the absence of ephrin-B2 binding [9, 13] . In addition, there may be an equilibrium where, in a fraction of the EphB4 molecules, the juxtamembrane and kinase domains are not engaged in autoinhibitory interactions even if unphosphorylated [51] , resulting in a basal level of kinase activity under unstimulated conditions. Molecules such as PI3K (phosphoinositide 3-kinase) p110γ , ephexin, and possibly others whose association with the Eph receptor juxtamembrane or kinase domain is independent of ephrin binding and receptor phosphorylation [52, 53] , may contribute to destabilize the autoinhibited conformation of the receptor. Additional work will be needed to conclusively elucidate the precise mechanisms underlying the ephrin-independent inhibition of cell-substrate adhesion and spreading by endogenous and transfected EphB4, and whether similar or different mechanisms are involved. Given the low transfection efficiency of MDA-MB-435p cells, we could not reliably determine the effect of transiently transfected EphB4 on overall β1 integrin levels.
Regardless, a decrease in integrin-mediated adhesion in cancer cells expressing EphB4 would be expected to inhibit their malignant properties. Previous genetic data have demonstrated that β1 integrin activity is absolutely required for tumorigenesis in a mouse mammary tumour model [54] . Furthermore, integrins have been shown to be important for the survival, migratory and invasive properties of many cancer cells [45, 55] . On the other hand, positive effects of EphB4 on the growth and directional migration/invasion of various cancer cell lines have also been reported using RNA interference and antisense oligonucleotide approaches [3] [4] [5] [6] [7] 9] . Under the conditions of our cell culture experiments, however, we did not detect inhibition of MDA-MB-435 and MCF7 cell growth due to EphB4 depletion. In addition, we found that random migration was increased in the absence of EphB4. Additional studies will be needed to elucidate the range of EphB4 receptor activities that do not require ephrin stimulation and their combined impact on the malignant properties of different types of cancer cells. However, investigating the overall effect of the ephrin-independent activities of EphB4 on tumour growth and metastasis in vivo will be challenging due to the interplay between EphB4 expressed in cancer cells and ephrin-B2 expressed in tumour blood vessels and the ability of both to signal through their cytoplasmic domains when bound to each other [56] . Nevertheless, the ephrin-independent effects that we have uncovered for EphB4 yield novel insights into the mode of action of Eph receptors in cancer cells and represent a new facet in the complexities of Eph receptor function. . from three coverslips. **P < 0.01 or ***P < 0.001 compared with control siRNA using one-way ANOVA and Bonferroni's post-hoc test. Each experiment was repeated twice with similar results.
